Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Core Insights - Candel Therapeutics, Inc. is focused on developing multimodal biological immunotherapies for cancer treatment and will present at the 7th Annual Glioblastoma Drug Development Summit in February 2026 [1] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - The lead product candidate from the adenovirus platform is aglatimagene besadenovec (CAN-2409), which has completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is undergoing a pivotal phase 3 trial in localized prostate cancer [4] Product Development - Linoserpaturev (CAN-3110) is the lead candidate from the HSV platform, currently in a phase 1b clinical trial for recurrent high-grade glioma [5] - In October 2023, results from a clinical trial indicated that linoserpaturev was well tolerated with no dose-limiting toxicity, showing improved median overall survival compared to historical controls after a single injection [3] - The company is supported by the Break Through Cancer foundation to evaluate repeated linoserpaturev injections in patients with recurrent glioblastoma [3] Upcoming Presentations - Dr. Francesca Barone will present insights on Candel's HSV-based platform and the linoserpaturev program at the summit, including a workshop on patient stratification and a conference presentation on integrating biomarkers and imaging [2][3]